EVO Platform Provides Ultrasensitive Multiomic Biomarker Discovery to Support Drug Development

SPARCs Enables Enhanced Detection of Key Protein Markers in the Blood

SPARCs enriched tumor and brain derived EVs (TDEVs and BDEVs) produce higher quantities of total protein and oncoproteins compared to total EV protein and total plasma protein. SPARCs enables more sensitive detection of key oncoproteins, such as KRAS. Samples are plasma of Glioblastoma patients (n=4). All samples analyzed via Mass Spectrometry.







EVO Platform is Compatible with Pre-clinical Animal Models

SPARCs enriched BDEVs from plasma of mouse models produces enough protein and RNA quantity for downstream analysis via Mass Spectrometry and RNA-Seq, respectively. Samples consist of drug-treated Customer Mouse Model Plasma, Mouse Control Plasma (CD-1), and Human Control Plasma.







EVO Platform Provides Ultrasensitive Multiomic Biomarker Discovery to Support Drug Development

EVO Enables Identification of Significant Number of Drug Targets from Blood

EVO produces a significant number of differentially expressed proteins (DEPs) in the blood of diseased patients versus healthy patients in multiple clinical studies. There is a high number of drug targets present in the DEPs data with clinical precedence (Source: ChEMBL), as well as a significant number of potentially novel targets to explore.



EVO Enables Going Beyond Tissue-based IHC to Support ADC Development and Deployment Utilizing a Blood-based Solution

EVO enables direct detection of a significant number of clinically relevant ADC targets in protein data in malignant glioma and NSCLC patients (Stage I and II). Utilizing an example of a high value ADC target, we demonstrate that TDEVs from diseased patients vary widely in ADC target protein abundance. When comparing high and low ADC expressing diseased patient subtypes, 587 differentially expressed proteins (DEPs) were identified. The DEPs indicate dysregulation of key proteins and signaling pathways associated with the ADC target.